scispace - formally typeset
Journal ArticleDOI

Microparticulates for ophthalmic drug delivery

Abhay Joshi
- 01 Jan 1994 - 
- Vol. 10, Iss: 1, pp 29-45
Reads0
Chats0
TLDR
The in vitro and in vivo studies have shown that this dosage form holds great promise for sustained drug release in the eye, however, several formulation challenges, including production of stable suspensions, uniform dose per unit volume, efficient drug entrapment, reproducible and large scale manufacturing, uniform particle size, etc., have to be addressed.
Abstract
Microparticulates are drug-containing small polymeric particles (erodible, non-erodible or ion-exchange resins) that are suspended in a liquid carrier medium. Upon administration of particle suspension in the eye, the particles reside at the delivery site (cul-de-sac, sub conjunctiva or vitreous cavity) and the drug is released from the particles through diffusion, chemical reaction, polymer degradation, or ion-exchange mechanism. Several distinct approaches have been used to formulate drugs in microparticulate dosage form for intraocular and topical application. These include erodible microparticulates, swelling mucoadhesive particulates, pH responsive microparticulates, nanoparticles/latex systems, ion-exchange resins, etc. Injection of bioerodible microparticulates in the vitreous for treating infections of posterior segment and the release of acceptable levels of drug up to two weeks has been demonstrated. Both corneal and non-corneal routes of drug entry in the eye from topical instillations are postulated. The in vitro and in vivo studies have shown that this dosage form holds great promise for sustained drug release in the eye. However, several formulation challenges, including production of stable suspensions, uniform dose per unit volume, efficient drug entrapment, reproducible and large scale manufacturing, uniform particle size, etc., have to be addressed. Fruitful resolution of technological challenges will result in a superior dosage form for both topical and intraocular ophthalmic application. Recent developments and future challenges of microparticulate ophthalmic drug delivery system are discussed in this review.

read more

Citations
More filters
Journal ArticleDOI

Nanosuspensions in drug delivery

TL;DR: Water insolubility issues of the past have provoked a paradigm change, which now offers novel solutions for innovative drugs of the future, and additional pharmacokinetic benefits of the drugs so formulated have come to be appreciated.
Journal ArticleDOI

The use of mucoadhesive polymers in ocular drug delivery.

TL;DR: In the present update on mucoadhesive ocular dosage forms, the tremendous advances in the biochemistry of mucins, the development of new polymers, the use of drug complexes and other technological advances are discussed.
Journal ArticleDOI

Ocular Preparations: The Formulation Approach

TL;DR: The barriers that decrease the bioavailability of an ophthalmic drug; the objectives to be considered in producing optimal formulations; and the approaches being used to improve the corneal penetration of a drug molecule and delay its elimination from the eye are reviewed.
Journal ArticleDOI

Biodegradable microspheres for vitreoretinal drug delivery

TL;DR: This article reviews the literature of biodegradable polymeric microspheres loaded with drugs, that have been investigated for delivery by intravitreous injection to treat diverse vitreoretinal diseases.
Journal ArticleDOI

Recent developments in ophthalmic drug delivery

TL;DR: Protein and peptide delivery, posterior drug delivery and non-aqueous vehicles are three new areas of interest in ophthalmic drug delivery, and this review will discuss recent progress and specific development issues relating to these drug delivery systems.
References
More filters
Journal ArticleDOI

Topical Ocular Drug Delivery: Recent Developments and Future Challenges

TL;DR: The focus of this review is on recent developments in topical ocular drug delivery systems relative to their success in overcoming the constraints imposed by the eye and to the improvements that have yet to be made.
Journal ArticleDOI

Drop size and initial dosing frequency problems of topically applied ophthalmic drugs

TL;DR: The multidrug data presented in this report constitute a strong argument for combination drug products whenever multi-drug therapy is indicated.
Journal ArticleDOI

Controlled Delivery Systems for Proteins Using Polyanhydride Microspheres

TL;DR: Activity studies demonstrated that the sonication process was primarily responsible for activity loss and it is likely that the protein interaction with FAD monomers permits formation of water-insoluble protein aggregates which slowly dissolve and diffuse out of the matrix, leading to delayed protein release.
Journal ArticleDOI

Ocular evaluation of methylcellulose vehicle in albino rabbits.

TL;DR: Comparison of the present study in rabbits to reported behavior in humans suggests that the vehicle viscosity influence is qualitatively similar but quantitatively different in both species, with the quantitative difference being due, in part, to the difference in rate of blinking and precorneal solution movement in rabbits as compared to humans.
Journal ArticleDOI

Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives

TL;DR: Physico-chemical properties and characterization of biodegradable nanoparticles, as well as drug payload, are discussed and special attention is given to the mechanism of bioerosion of nanoparticles both in vitro and in vivo.
Related Papers (5)